Shanghai Yizhong Pharmaceutical Co Ltd (688091) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shanghai Yizhong Pharmaceutical Co Ltd (688091) has a cash flow conversion efficiency ratio of 0.014x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥21.03 Million ≈ $3.08 Million USD) by net assets (CN¥1.46 Billion ≈ $213.78 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 688091 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Shanghai Yizhong Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Shanghai Yizhong Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Shanghai Yizhong Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Yizhong Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Chunhui Intelligent Control Co. Ltd.
SHE:300943
|
-0.001x |
|
Jiangsu Bojun Industrial Technology Co. Ltd
SHE:300926
|
0.021x |
|
Qingdao Haier Biomedical Co Ltd
SHG:688139
|
0.002x |
|
Everi Holdings Inc
NYSE:EVRI
|
1.295x |
|
CSG Holding Co Ltd
SHE:000012
|
0.033x |
|
Treehouse Foods Inc
NYSE:THS
|
0.030x |
|
Biotage AB
ST:BIOT
|
0.011x |
|
Grupo Televisa S.A.B.
F:TLV
|
0.100x |
Annual Cash Flow Conversion Efficiency for Shanghai Yizhong Pharmaceutical Co Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Shanghai Yizhong Pharmaceutical Co Ltd from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see 688091 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥1.41 Billion ≈ $205.60 Million |
CN¥39.44 Million ≈ $5.77 Million |
0.028x | -52.50% |
| 2023-12-31 | CN¥1.46 Billion ≈ $214.35 Million |
CN¥86.55 Million ≈ $12.67 Million |
0.059x | -29.64% |
| 2022-12-31 | CN¥1.32 Billion ≈ $193.04 Million |
CN¥110.78 Million ≈ $16.21 Million |
0.084x | +302.36% |
| 2021-12-31 | CN¥1.18 Billion ≈ $172.02 Million |
CN¥-48.78 Million ≈ $-7.14 Million |
-0.041x | +50.00% |
| 2020-12-31 | CN¥243.51 Million ≈ $35.63 Million |
CN¥-20.21 Million ≈ $-2.96 Million |
-0.083x | +7.88% |
| 2019-12-31 | CN¥265.35 Million ≈ $38.83 Million |
CN¥-23.91 Million ≈ $-3.50 Million |
-0.090x | -78.92% |
| 2018-12-31 | CN¥212.18 Million ≈ $31.05 Million |
CN¥-10.68 Million ≈ $-1.56 Million |
-0.050x | +13.58% |
| 2017-12-31 | CN¥197.57 Million ≈ $28.91 Million |
CN¥-11.51 Million ≈ $-1.68 Million |
-0.058x | -- |
About Shanghai Yizhong Pharmaceutical Co Ltd
Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the development of anti-tumor drugs and related products in China. It also offers paclitaxel polymer nanomicelles for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, gynecological tumors, etc. The company was… Read more